832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
Work
Year: 2022
Type: article
Source: Annals of Oncology
Institutions University Hospital of Zurich, University Hospital Heidelberg, National Center for Tumor Diseases, Heidelberg University, Sidney Kimmel Cancer Center +10 more
Cites:
Cited by: 3
Related to: 10
FWCI: 0.409
Citation percentile (by year/subfield): 52.17
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze